Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ

BACKGROUND: The treatment efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like erlotinib has not met expectations for glioblastoma therapy, even for EGFR-overexpressing tumors. We determined possible mechanisms of therapy resistance using the unique BS153 glioblastoma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schulte, Alexander, Liffers, Katrin, Kathagen, Annegret, Riethdorf, Sabine, Zapf, Svenja, Merlo, Adrian, Kolbe, Katharina, Westphal, Manfred, Lamszus, Katrin
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3779041/
https://ncbi.nlm.nih.gov/pubmed/23877316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados